Home Thought-Leader Perspective

Thought-Leader Perspective

Articles by lung cancer leaders who provide their perspective about issues germane to the field of thoracic oncology.

Latest

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

lungcanc

JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS Benefit

c-MET Antibody–Drug Conjugates: Misconceptions Corrected, Excitement Explained— An Interview with Dr. Karen Kelly

An Interview with Dr. Federico Cappuzzo: Checkpoint Inhibitors Have Replaced Old Strategies

Thoughts on IMpower 150: Latest FDA Approval for Atezolizumab Misses the Mark

Dr. Howard ‘Skip’ Burris III Shares His Views on Clinical Trial...

lungcanc

Q&A with Dr. D. Ross Camidge

lungcanc

Keeping It Personal: CMS-Proposed Coverage Restrictions for NGS Challenge Innovation in...

lungcanc

Q&A with TMB Expert Dr. Solange Peters

lungcanc

Q&A with the New IASLC President

lungcanc

An American Perspective on the European Lung Cancer Screening Implementation Plans

lungcanc

Erlotinib, Crizotinib, Nivolumab: Big Three in ALCHEMIST Platform

lungcanc

Commentary Regarding Immune Checkpoint Inhibitors

lungcanc

Q&A with Jamie E. Chaft, MD, Regarding the ALCHEMIST Platform

lungcanc

A Surprising Career Advances Cancer Research: Margaret Foti, MD, PhD (hc)

lungcanc

12 3 Page 1 of 3

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib